Exscientia (NASDAQ:EXAI) Stock Price Up 6.9%

Exscientia plc (NASDAQ:EXAI) shares rose 6.9% during trading on Monday . The stock traded as high as $5.01 and last traded at $4.99. Approximately 341,928 shares traded hands during trading, a decline of 50% from the average daily volume of 686,375 shares. The stock had previously closed at $4.67.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 price target on shares of Exscientia in a research note on Monday, April 22nd.

Exscientia Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22. The stock has a market cap of $604.45 million, a P/E ratio of -3.38 and a beta of 0.82. The stock has a 50-day simple moving average of $5.41 and a 200-day simple moving average of $5.81.

Exscientia (NASDAQ:EXAI) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. Research analysts forecast that Exscientia plc will post -1.76 earnings per share for the current year.

Hedge Funds Weigh In On Exscientia

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Exscientia by 112.1% in the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after buying an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Exscientia by 359.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after acquiring an additional 4,104 shares during the last quarter. Walled Lake Planning & Wealth Management LLC acquired a new position in shares of Exscientia during the fourth quarter worth $64,000. Rathbones Group PLC bought a new stake in shares of Exscientia in the third quarter worth $47,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in Exscientia in the third quarter valued at $58,000. 41.58% of the stock is currently owned by institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.